Immunosuppressive therapy for @entity2590 : efficacy of @entity1667 pulse therapy with or without XXXX .

@entity1667 @entity1 @entity7139 @entity2590 @entity1503 @entity205 @entity4018 @entity236 @entity309 @entity617
We investigated whether immunosuppressive therapy using @entity1667 (mPSL) with or without @entity205 (CsA) could benefit @entity1 with @entity2590 ( @entity2590 ). Eligibility criteria for this study were a clinical diagnosis of @entity2590 with less than 5% blast in peripheral blood, less than 10% blast in bone marrow and advanced @entity1503 . Among 73 @entity1 with @entity2590 , 18 eligible and consecutive @entity1 (8 @entity1 and 10 @entity1 ), aged 48 to 87 years (median: 66.5 years) were assigned to receive mPSL pulse therapy (1,000 mg daily for 3 consecutive days, followed by tapering oral @entity617 ; n= 12) or mPSL pulse with CsA therapy (4 to 5 mg/kg administered twice daily; n= 6). Six of 18 @entity1 (33.3%; 3 of 10 @entity1 with @entity309 , 2 of 6 @entity1 with @entity7139 , 1 of 2 @entity1 with CMMoL) responded to immunosuppressive therapy. Four @entity1 responded to mPSL pulse alone, and two @entity1 responded to mPSL pulse with CsA. One of 6 @entity1 with @entity236 and 5 of 12 @entity1 with normocellular or @entity236 responded to immunosuppressive therapy. No @entity1 with @entity4018 responded to the therapy. The duration of response ranged from 4 to 59 months (median: 14 months). Although a significant difference was observed between responders and nonresponders in the survival rate ( P<0.05), no significant difference was found in clinical characteristics at entry between responders and nonresponders. In responders, mean hemoglobin levels were significantly increased ( P<0.01), and the required red cell transfusion dose was significantly reduced ( P<0.01). It is possible that immunosuppressive therapy might be effective for a certain subset of @entity1 with @entity2590 .
